These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34455300)

  • 21. Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.
    Chang I; Mitsui Y; Fukuhara S; Gill A; Wong DK; Yamamura S; Shahryari V; Tabatabai ZL; Dahiya R; Shin DM; Tanaka Y
    Oncotarget; 2015 Apr; 6(10):7774-87. PubMed ID: 25860934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of 2-arylbenzo[
    Dong J; Wang Z; Meng Q; Zhang Q; Huang G; Cui J; Li S
    RSC Adv; 2018 Apr; 8(27):15009-15020. PubMed ID: 35541321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance.
    McFadyen MC; McLeod HL; Jackson FC; Melvin WT; Doehmer J; Murray GI
    Biochem Pharmacol; 2001 Jul; 62(2):207-12. PubMed ID: 11389879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of CYP1B1-specific candidate inhibitors using combination of in silico screening, integrated knowledge-based filtering, and molecular dynamics simulations.
    Kumar R; Gupta D
    Chem Biol Drug Des; 2016 Nov; 88(5):730-739. PubMed ID: 27300691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxicity and cisplatin resistance.
    Sonawane VR; Siddique MUM; Gatchie L; Williams IS; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
    Eur J Pharm Sci; 2019 Apr; 131():177-194. PubMed ID: 30776468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1.
    Wang A; Savas U; Stout CD; Johnson EF
    J Biol Chem; 2011 Feb; 286(7):5736-43. PubMed ID: 21147782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity.
    Dutour R; Roy J; Cortés-Benítez F; Maltais R; Poirier D
    J Med Chem; 2018 Oct; 61(20):9229-9245. PubMed ID: 30216063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
    Pastina I; Giovannetti E; Chioni A; Sissung TM; Crea F; Orlandini C; Price DK; Cianci C; Figg WD; Ricci S; Danesi R
    BMC Cancer; 2010 Sep; 10():511. PubMed ID: 20875115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
    Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
    Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biphenyl urea derivatives as selective CYP1B1 inhibitors.
    Mohd Siddique MU; McCann GJ; Sonawane V; Horley N; Williams IS; Joshi P; Bharate SB; Jayaprakash V; Sinha BN; Chaudhuri B
    Org Biomol Chem; 2016 Sep; 14(38):8931-8936. PubMed ID: 27714268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and Synthesis of Novel Near-Infrared Fluorescence Probes Based on an Open Conformation of a Cytochrome P450 1B1 Complex for Molecular Imaging of Colorectal Tumors.
    Chen D; Li R; Shao Q; Wu Z; Cui J; Meng Q; Li S
    J Med Chem; 2023 Dec; 66(23):16032-16050. PubMed ID: 38031326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme.
    Bournique B; Lemarié A
    Drug Metab Dispos; 2002 Nov; 30(11):1149-52. PubMed ID: 12386117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
    Lee D; Perez P; Jackson W; Chin T; Galbreath M; Fronczek FR; Isovitsch R; Iimoto DS
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3243-3247. PubMed ID: 27265259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.
    Zhu Z; Mu Y; Qi C; Wang J; Xi G; Guo J; Mi R; Zhao F
    Int J Mol Med; 2015 Feb; 35(2):340-8. PubMed ID: 25516145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives.
    Poirier D; Roy J; Cortés-Benítez F; Dutour R
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5272-5276. PubMed ID: 27687674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quercetin-glutamic acid conjugate with a non-hydrolysable linker; a novel scaffold for multidrug resistance reversal agents through inhibition of P-glycoprotein.
    Kim MK; Kim Y; Choo H; Chong Y
    Bioorg Med Chem; 2017 Feb; 25(3):1219-1226. PubMed ID: 28043777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.
    Ortuzar N; Karu K; Presa D; Morais GR; Sheldrake HM; Shnyder SD; Barnieh FM; Loadman PM; Patterson LH; Pors K; Searcey M
    Bioorg Med Chem; 2021 Jun; 40():116167. PubMed ID: 33932713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.
    Wang Z; Chen Y; Drbohlav LM; Wu JQ; Wang MZ
    J Biomol Screen; 2016 Dec; 21(10):1090-1099. PubMed ID: 28139960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.